Aprepitant in the Treatment of Subacute Sclerosing Panencephalitis: A Randomized, Double-Blind, Placebo-Controlled Study

Oncel, Ibrahim; SANCAR, MESUT; KONUŞKAN, BAHADIR; Arioz, Filiz; TEZCAN, SONGÜL; ARMAN KANDIRMAZ, EMİNE; PARLAK, ŞAFAK; GÜMELER, EKİM; Anlar, Banu

doi:10.1016/j.pediatrneurol.2020.05.009

Aprepitant in the Treatment of Subacute Sclerosing Panencephalitis: A Randomized, Double-Blind, Placebo-Controlled Study

Copy For Citation

Oncel I., SANCAR M., KONUŞKAN B., Arioz F., TEZCAN S., ARMAN KANDIRMAZ E., ...More

PEDIATRIC NEUROLOGY, vol.110, pp.59-63, 2020 (SCI-Expanded)

Publication Type: Article / Article
Volume: 110
Publication Date: 2020
Doi Number: 10.1016/j.pediatrneurol.2020.05.009
Journal Name: PEDIATRIC NEUROLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
Page Numbers: pp.59-63
Hacettepe University Affiliated: Yes

Abstract

Background: Aprepitant is a neurokinin-1 receptor antagonist approved for the treatment of chemotherapy-induced nausea. We aimed to investigate the safety and efficacy of aprepitant in patients with subacute sclerosing panencephalitis.